P/E ratio for Chugai Pharmaceutical (4519.T)
P/E ratio as of April 2024 (TTM): 21.2
According to Chugai Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 21.1574. At the end of 2022 the company had a P/E ratio of 14.8.
P/E ratio history for Chugai Pharmaceutical from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 14.8 | -27% |
| 2021 | 20.3 | -51.88% |
| 2020 | 42.1 | 20.27% |
| 2019 | 35.0 | -7.19% |
| 2018 | 37.7 | -13% |
| 2017 | 43.4 | 26.85% |
| 2016 | 34.2 | -9.68% |
| 2015 | 37.9 | 19.46% |
| 2014 | 31.7 | 27.42% |
| 2013 | 24.9 | 27.49% |
| 2012 | 19.5 | -0.46% |
| 2011 | 19.6 | 0.15% |
| 2010 | 19.6 | 14.7% |
| 2009 | 17.1 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.